• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人补体受体1前三个短共有重复序列模块在大肠杆菌中的过表达、折叠、纯化及特性分析

Overexpression in Escherichia coli, folding, purification, and characterization of the first three short consensus repeat modules of human complement receptor type 1.

作者信息

Dodd I, Mossakowska D E, Camilleri P, Haran M, Hensley P, Lawlor E J, McBay D L, Pindar W, Smith R A

机构信息

Department of Protein Chemistry, SmithKline Beecham Pharmaceuticals, Epsom, Surrey, United Kingdom.

出版信息

Protein Expr Purif. 1995 Dec;6(6):727-36. doi: 10.1006/prep.1995.0003.

DOI:10.1006/prep.1995.0003
PMID:8746624
Abstract

We have developed a simple expression, isolation, and folding protocol for an SCR oligomer comprising the first three SCRs of complement receptor Type 1 (C3b/C4b receptor, CD35). A T7 RNA polymerase expression system in Escherichia coli was used to express the oligomer as inclusion bodies. The oligomer was recovered from solubilized inclusion bodies using batch adsorption on SP-Sepharose. The oligomer was folded by one-step dilution in 20 mM ethanolamine/1 mM EDTA supplemented with 1 mM GSH/0.5 mM GSSG. The folded material was processed to a concentrated (> 20 mg/ml), usable product of greater than 98% purity using a combination of ultrafiltration, ammonium sulfate treatment, hydrophobic interaction, and size-exclusion chromatography. The yield of folded material varied between 6 and 15 mg/liter culture. The oxidation states of the 12 cysteine residues in SCR(1-3) were identified by HPLC of peptide fragments from a tryptic digest using dual UV/fluorescence detection, collection of selected peaks, and N-terminal sequencing. This methodology confirmed the expected location of disulfide bridges. Equilibrium and velocity sedimentation studies are interpreted in terms of a single sedimenting species with molecular weights of 21,629 and 21,063 by these respective techniques. These values compare to the predicted molecular weight, from amino acid composition, of 21,817. The hydrodynamic properties of the molecule indicate that it is asymmetric with an axial ratio of 1:5.2 or equivalent dimensions of 21 x 110 A. SCR(1-3) has an unusual CD spectrum exhibiting a broad maximum at 220-230 nm and a minimum at 190 nm. There was little evidence of classical secondary structure. The product exhibited concentration-dependent inhibition of complement-mediated lysis of sensitized sheep red blood cells.

摘要

我们已经开发出一种针对包含补体1型受体(C3b/C4b受体,CD35)前三个短共识重复序列(SCR)的SCR寡聚体的简单表达、分离和折叠方案。利用大肠杆菌中的T7 RNA聚合酶表达系统将该寡聚体表达为包涵体。通过在SP-琼脂糖凝胶上进行批量吸附,从溶解的包涵体中回收该寡聚体。通过在补充有1 mM还原型谷胱甘肽/0.5 mM氧化型谷胱甘肽的20 mM乙醇胺/1 mM乙二胺四乙酸中一步稀释来折叠该寡聚体。使用超滤、硫酸铵处理、疏水相互作用和尺寸排阻色谱相结合的方法,将折叠后的材料加工成浓度大于20 mg/ml、纯度大于98%的可用产品。折叠材料的产量在每升培养物6至15 mg之间变化。通过使用双紫外/荧光检测、收集选定峰和N端测序,对胰蛋白酶消化产生的肽片段进行高效液相色谱分析,确定了SCR(1-3)中12个半胱氨酸残基的氧化状态。该方法证实了二硫键的预期位置。平衡沉降和速度沉降研究通过这些各自的技术解释为分子量分别为21,629和21,063的单一沉降物种。这些值与根据氨基酸组成预测的分子量21,817相比。该分子的流体动力学性质表明它是不对称的,轴比为1:5.2或等效尺寸为21 x 110 Å。SCR(1-3)具有不寻常的圆二色光谱,在220 - 230 nm处有一个宽峰,在190 nm处有一个最小值。几乎没有经典二级结构的证据。该产品表现出对补体介导的致敏绵羊红细胞裂解的浓度依赖性抑制作用。

相似文献

1
Overexpression in Escherichia coli, folding, purification, and characterization of the first three short consensus repeat modules of human complement receptor type 1.人补体受体1前三个短共有重复序列模块在大肠杆菌中的过表达、折叠、纯化及特性分析
Protein Expr Purif. 1995 Dec;6(6):727-36. doi: 10.1006/prep.1995.0003.
2
Structure-activity relationships within the N-terminal short consensus repeats (SCR) of human CR1 (C3b/C4b receptor, CD35): SCR 3 plays a critical role in inhibition of the classical and alternative pathways of complement activation.人类CR1(C3b/C4b受体,CD35)N端短共有重复序列(SCR)内的结构-活性关系:SCR 3在抑制补体激活的经典途径和替代途径中起关键作用。
Eur J Immunol. 1999 Jun;29(6):1955-65. doi: 10.1002/(SICI)1521-4141(199906)29:06<1955::AID-IMMU1955>3.0.CO;2-O.
3
Primary sequence of an alternatively spliced form of CR1. Candidate for the 75,000 M(r) complement receptor expressed on chimpanzee erythrocytes.CR1可变剪接形式的一级序列。在黑猩猩红细胞上表达的75,000 M(r)补体受体的候选物。
J Immunol. 1994 Jul 15;153(2):691-700.
4
Independently melting modules and highly structured intermodular junctions within complement receptor type 1.1型补体受体内的独立融化模块和高度结构化的模块间连接
Biochemistry. 1999 Jun 1;38(22):7019-31. doi: 10.1021/bi982453a.
5
Folding, calcium binding, and structural characterization of a concatemer of the first and second ligand-binding modules of the low-density lipoprotein receptor.低密度脂蛋白受体第一和第二配体结合模块串联体的折叠、钙结合及结构表征
Biochemistry. 1998 Aug 4;37(31):10994-1002. doi: 10.1021/bi980452c.
6
Soybean disease resistance protein RHG1-LRR domain expressed, purified and refolded from Escherichia coli inclusion bodies: preparation for a functional analysis.从大肠杆菌包涵体中表达、纯化和重折叠的大豆抗病蛋白RHG1-LRR结构域:功能分析的准备工作。
Protein Expr Purif. 2007 Jun;53(2):346-55. doi: 10.1016/j.pep.2006.12.017. Epub 2006 Dec 27.
7
The partly folded back solution structure arrangement of the 30 SCR domains in human complement receptor type 1 (CR1) permits access to its C3b and C4b ligands.人1型补体受体(CR1)中30个短共识重复序列(SCR)结构域部分回折的溶液结构排列方式使其能够接近其C3b和C4b配体。
J Mol Biol. 2008 Jan 4;375(1):102-18. doi: 10.1016/j.jmb.2007.09.085. Epub 2007 Oct 3.
8
Production and characterization of the functional fragment of pneumococcal surface protein A.肺炎球菌表面蛋白A功能片段的制备与特性分析
Arch Biochem Biophys. 2000 Jan 1;373(1):116-25. doi: 10.1006/abbi.1999.1544.
9
Refolding, purification, and characterization of human erythropoietin binding protein produced in Escherichia coli.在大肠杆菌中产生的人促红细胞生成素结合蛋白的复性、纯化及特性鉴定
Protein Expr Purif. 1996 Feb;7(1):104-13. doi: 10.1006/prep.1996.0014.
10
Refolding, purification, and activation of miniplasminogen and microplasminogen isolated from E. coli inclusion bodies.从大肠杆菌包涵体中分离出的微型纤溶酶原和微纤溶酶原的复性、纯化及激活
Protein Expr Purif. 2007 Apr;52(2):395-402. doi: 10.1016/j.pep.2006.10.012. Epub 2006 Oct 26.

引用本文的文献

1
Multicentre, multi-arm, double-blind randomised placebo-controlled dose-finding trial investigating the safety and Efficacy of MirococePt (APT070) In Reducing delayed graft function In the Kidney ALlograft (EMPIRIKAL-2): study protocol for a randomised controlled trial.多中心、多臂、双盲随机安慰剂对照剂量探索试验,旨在研究米罗可普特(APT070)降低肾移植术后移植肾功能延迟恢复的安全性和有效性(EMPIRIKAL-2):一项随机对照试验的研究方案
BMJ Open. 2025 Mar 6;15(3):e097029. doi: 10.1136/bmjopen-2024-097029.
2
The Production of Complement Inhibitor Proteins in Mammalian Cell Lines-Light at the End of the Tunnel?哺乳动物细胞系中补体抑制蛋白的生产——曙光在前?
Biomedicines. 2024 Mar 14;12(3):646. doi: 10.3390/biomedicines12030646.
3
Clinical promise of next-generation complement therapeutics.
下一代补体治疗药物的临床前景。
Nat Rev Drug Discov. 2019 Sep;18(9):707-729. doi: 10.1038/s41573-019-0031-6. Epub 2019 Jul 19.
4
Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.补体治疗与纳米医学相遇:用 CD55 的可溶性结构域克服纳米药物的人补体激活和白细胞摄取。
J Control Release. 2019 May 28;302:181-189. doi: 10.1016/j.jconrel.2019.04.009. Epub 2019 Apr 8.
5
A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial.米罗西普(APT070)预防同种异体肾移植缺血再灌注损伤疗效的双盲随机对照研究(EMPIRIKAL):一项随机对照试验的研究方案
Trials. 2017 Jun 6;18(1):255. doi: 10.1186/s13063-017-1972-x.
6
APT070 (mirococept), a membrane-localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model.APT070(米罗西普)是一种定位于细胞膜的C3转化酶抑制剂,在人源化小鼠模型中,它在体外和体内均可减轻早期人类胰岛移植损伤。
Br J Pharmacol. 2016 Feb;173(3):575-87. doi: 10.1111/bph.13388. Epub 2016 Jan 11.
7
Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complement.放射性核素标记的重组补体受体 2:一种用于成像激活补体的潜在新型放射性药物。
PLoS One. 2011 Apr 6;6(4):e18275. doi: 10.1371/journal.pone.0018275.
8
Tissue distribution and functional analysis of Sushi domain-containing protein 4.Sushi 结构域蛋白 4 的组织分布与功能分析
Am J Pathol. 2010 May;176(5):2378-84. doi: 10.2353/ajpath.2010.091036. Epub 2010 Mar 26.
9
Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins.静电建模可预测正痘病毒补体控制蛋白的活性。
J Immunol. 2005 Feb 15;174(4):2143-51. doi: 10.4049/jimmunol.174.4.2143.
10
Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.在大肠杆菌中表达的可溶性人衰变加速因子的生物学活性、膜靶向修饰及结晶
Protein Sci. 2004 Sep;13(9):2406-15. doi: 10.1110/ps.03455604.